KalVista Pharmaceuticals Announces Inducement Grants for New Employees Under Nasdaq Rule 5635(c)(4)

Reuters
2025/06/04
KalVista Pharmaceuticals Announces Inducement Grants for New Employees Under Nasdaq Rule 5635(c)(4)

KalVista Pharmaceuticals Inc. has announced the issuance of inducement grants for five newly-hired employees as part of their compensation package. The company's board of directors' compensation committee approved options to purchase a total of 50,000 shares of KalVista common stock, effective June 1, 2025. These stock options are designed to be inducements material to the employees' decision to join the company. The exercise price of the options is set at the closing price of KalVista common stock on the grant date. The vesting schedule includes one-fourth of the options vesting after one year, with the remainder vesting in equal monthly installments over the following three years, contingent on the employees' continued service. Each stock option carries a 10-year term and adheres to the terms of KalVista's Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250603633530) on June 03, 2025, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10